Daniel Marsh

Daniel Marsh

Senior Markets Analyst

Daniel Marsh is a senior markets analyst at StockTi with over 12 years of experience covering U.S. and global equity markets. He holds a CFA charter and previously worked as an equity research associate at a major Wall Street firm. Daniel specializes in macroeconomic analysis, market trends, and cross-sector investment themes. His work focuses on translating complex market data into actionable insights for individual and institutional investors.

Markets, Economy, Analysis 4,435 articles

Articles by Daniel Marsh

NextEra Energy Slips on $66.8B Dominion Deal; Market Eyes AI Demand
Markets

NextEra Energy Slips on $66.8B Dominion Deal; Market Eyes AI Demand

NextEra Energy shares dropped 4.6% after unveiling a $66.8 billion stock merger with Dominion Energy, creating a utility giant serving 10 million customers. The deal targets rising AI data center power demand.

NEE D DUK SO XLU
T1 Energy Shares Jump on Institutional Filing, Solar Plans in Focus
Markets

T1 Energy Shares Jump on Institutional Filing, Solar Plans in Focus

T1 Energy shares surged 23% after a regulatory filing showed Situational Awareness LP held 10 million shares. The solar maker's Q1 revenue of $177.6M and on-schedule Austin plant fuel momentum.

Warner Bros. Discovery Stock Trades Below Intrinsic Value Amid Merger Speculation
Markets

Warner Bros. Discovery Stock Trades Below Intrinsic Value Amid Merger Speculation

Warner Bros. Discovery shares trade at $27.10, roughly 10% below some intrinsic value estimates but above a cited fair value of $18.17. Analysts remain divided amid merger talks with Paramount and regulatory uncertainty.

WBD
Wall Street Rally Falters as Oil and Yields Weigh on Tech
Markets

Wall Street Rally Falters as Oil and Yields Weigh on Tech

U.S. stocks were mixed Monday as rising oil and Treasury yields pressured tech. The Nasdaq slid 0.5%, while energy stocks gained. Dominion Energy jumped 9.4% on merger news.

NVDA AMD NEE D REGN HD WMT USO GLD XLE XLK
Regeneron Plunges 10% on Melanoma Drug Trial Failure
Markets

Regeneron Plunges 10% on Melanoma Drug Trial Failure

Regeneron Pharmaceuticals shares dropped 9.8% Monday after its late-stage melanoma drug trial with fianlimab failed to meet its primary endpoint, missing statistical significance versus Merck's Keytruda.

REGN MRK BMY
Sunshine Biopharma Shares Swing Wildly After $6M Offering
Markets

Sunshine Biopharma Shares Swing Wildly After $6M Offering

Sunshine Biopharma shares experienced extreme volatility Monday after a $6M public offering, surging 516% before closing up 78% at $0.51.

SBFM
NextEra's $66.8B Dominion Deal Targets AI Data Center Demand
Markets

NextEra's $66.8B Dominion Deal Targets AI Data Center Demand

NextEra Energy agreed to acquire Dominion Energy in a $66.8B all-stock deal, sending Dominion shares up 9.4% as AI data centers drive power demand.

NEE D XLU
Goosehead Insurance Shares Surge 12% After JPMorgan Target Cut
Markets

Goosehead Insurance Shares Surge 12% After JPMorgan Target Cut

Goosehead Insurance shares jumped 12% to $42.14, recovering from recent lows after JPMorgan cut its price target to $55. Q1 revenue rose 23% to $93.1M, with net income tripling.

GSHD JPM
Markets Wobble as Iran Tensions Persist; Oil and Yields Rise
Markets

Markets Wobble as Iran Tensions Persist; Oil and Yields Rise

U.S. stocks closed mixed Monday as oil prices rose after Trump paused an Iran strike, while rising bond yields pressured tech and AI shares.

NVDA SNDK BE USO GLD
DTE Energy Issues 1 GW Clean Power RFP, Michigan Developers Face 2029 Deadline
Markets

DTE Energy Issues 1 GW Clean Power RFP, Michigan Developers Face 2029 Deadline

DTE Energy seeks 1 GW of renewable capacity in Michigan, with projects required to begin operations by end of 2029, aligning with state clean energy goals.

DTE CMS
AMC Shares Rise 6.25% Amid Dilution Concerns and Menu Expansion
Markets

AMC Shares Rise 6.25% Amid Dilution Concerns and Menu Expansion

AMC Entertainment shares rose 6.25% to $1.36 on Monday, outpacing broader markets, but caution lingers due to dilution and debt concerns.

AMC
USA Rare Earth Plunges 12.8% as Defense Lobby Delays Chinese Magnet Ban
Markets

USA Rare Earth Plunges 12.8% as Defense Lobby Delays Chinese Magnet Ban

USA Rare Earth shares dropped 12.8% to $21.28 Monday after defense firms pushed to delay a ban on Chinese rare-earth magnets. The company posted $5.7M in Q1 revenue and received a $14.18M Texas grant.

USAR MP